Genmab A/S (NASDAQ:GMAB) Announces Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Genmab A/S (NASDAQ:GMAB) released its quarterly earnings results on Thursday. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.36 by $0.20, Zacks reports. Genmab A/S had a net margin of 16.97% and a return on equity of 13.96%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.20 billion.

Here are the key takeaways from Genmab A/S’s conference call:

• Genmab reported 22% revenue growth for the first nine months of 2026 and 9% growth in adjusted operating profit. Management said growth is becoming more diversified, with roughly half of revenue growth coming from outside DARZALEX.
• Commercial momentum continued: EPKINLY sales rose 47% to $491 million, while TIVDAK sales increased 9% to $131 million. Genmab highlighted broader EPKINLY adoption and continued TIVDAK growth in Japan and Europe.
• The company announced three positive Phase III readouts in October: EPKINLY in frontline DLBCL, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer. Genmab sees potential launches beginning in 2027, though the medicines remain subject to regulatory review.
• Genmab maintained its 2026 guidance, expects revenue in the upper part of its $4.325–$4.525 billion range, and said adjusted operating profit should finish above the midpoint of its guidance range.
• Management cautioned that fourth-quarter operating expenses will rise significantly due to manufacturing, clinical development, and launch-readiness work for Rina-S and petosemtamab.

Genmab A/S Price Performance

GMAB stock traded up $0.89 on Friday, reaching $53.63. The company had a trading volume of 7,827,783 shares, compared to its average volume of 6,032,240. The company’s fifty day moving average is $39.18 and its 200 day moving average is $31.11. The company has a market cap of $33.47 billion, a P/E ratio of 41.25, a PEG ratio of 2.11 and a beta of 0.73. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $59.97.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GMAB. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. JPMorgan Chase & Co. raised shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a report on Monday, October 26th. TD Cowen upped their target price on shares of Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, October 26th. Guggenheim increased their target price on shares of Genmab A/S from $58.00 to $80.00 and gave the company a “buy” rating in a report on Friday, October 30th. Finally, Truist Financial reiterated a “buy” rating and set a $67.00 price target (up from $45.00) on shares of Genmab A/S in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $53.61.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.

The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Genmab operates internationally, with activities across Europe, North America and Asia.